The traditional view of GLP-1 as a mere glycemic regulator is officially obsolete in the face of recent breakthroughs in neuroprotection and…
GLP-1
The efficacy of tirzepatide is not merely the sum of two metabolic hormones, but the result of a precisely engineered biased dual-agonism that…
The SURMOUNT-MAINTAIN trial results from May 2026 revealed that participants on the maximum tolerated dose of tirzepatide maintained a mean weight…
While dual-agonists changed the metabolic research landscape, the December 2025 TRIUMPH-4 trial results revealed that the retatrutide peptide…